CDC endorses advisory panel's recommendation expressing preference for mRNA COVID-19 vaccines over the Johnson & Johnson vaccine



An advisory panel to the Centers for Disease Control and prevention voted unanimously on Thursday to recommend mRNA COVID-19 vaccines as the "preferred" options compared to the Janssen COVID-19 vaccine, and the CDC has endorsed the panel's assessment.

Johnson & Johnson's Janssen vaccine has been linked to blood clots in some people.

The government has verified the clotting issue in 37 women and 17 men, and of nine people who have died, two were men, Dr. Isaac See of the CDC said, according to the Associated Press, which also reported that See noted that two more deaths are also suspected. NBC News reported that See told the committee that through late August, 54 cases of the problem were found following vaccination with the J&J vaccine.

The CDC reports that more than 16 million people have been fully vaccinated in the U.S. with the Johnson & Johnson Janssen vaccine, while more than 17 million doses have been administered.

While full vaccination with the J&J vaccine involves just one shot, full vaccination for the Moderna and Pfizer vaccines involves receiving two shots.

The CDC has endorsed the recommendation from the Advisory Committee on Immunization Practices.

"ACIP’s unanimous recommendation followed a robust discussion of the latest evidence on vaccine effectiveness, vaccine safety and rare adverse events, and consideration of the U.S. vaccine supply. The U.S. supply of mRNA vaccines is abundant – with nearly 100 million doses in the field for immediate use," the CDC said.

"Given the current state of the pandemic both here and around the world, the ACIP reaffirmed that receiving any vaccine is better than being unvaccinated. Individuals who are unable or unwilling to receive an mRNA vaccine will continue to have access to Johnson & Johnson’s COVID-19 vaccine," the agency noted.

WATCH: Why are you STILL wearing a mask?



On May 13, 2021, Biden announced a COVID response update for mask guidelines, as per the CDC, that no longer required vaccinated individuals to wear masks. The CDC has since changed its recommendations for masking. Here are the most recent CDC guidelines.

In this video, Steven Crowder hit the streets of Dallas, Texas, to find out what Texans think and masks, mandates, and masked mandates. He conducted a formal survey, appealing directly to the American people to answer why a vaccinated person still chose to wear a mask.

After a short time, Crowder observed a few people wearing masks. He decided to modify his premise and asked how citizens felt about the vaccine mandate. Steven found that many Texans believe that the government should not force people to receive a vaccine.

Since Biden's May 13 mask update, the president announced that employers would be required to enforce a vaccine mandate for businesses with 100 or more employees. This was a source of concern for many of those surveyed.

In a clear pattern, Crowder noticed that black Americans expressed distrust of the government. He noted that "white men who work in the mainstream media" refer to this distrust — as it relates to the COVID vaccine — as "vaccine hesitancy." But Crowder found that this so-called "hesitancy," in truth, sounded a lot more like a healthy dose of weighing the risk vs. the reward.

One Fort Worth woman explained why she wears a mask instead of receiving the vaccine. Due to the relatively new coronavirus and the even newer vaccine, she will weigh her options and make decisions for her health as more information becomes available.

Watch the clip to see what Americans had to say about masks and vaccine mandates. Can't watch? Download the podcast here.


Want more from Steven Crowder?

To enjoy more of Steven's uncensored late-night comedy that's actually funny, join Mug Club — the only place for all of Crowder uncensored and on demand.

Why The WTO Shouldn’t Break U.S. COVID Vaccine Patents

In the coming months, as the WTO decides how to proceed with this controversial decision, they must consider not just the current pandemic but the future of pharmaceutical innovations.